Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what assessment they have made of the ability of NHS England and the National Institute for Health and Care Excellence (NICE) to introduce the new Cancer Drugs Fund (CDF) process from 1 April and manage the transition from the old CDF in relation to (1) timelines for the publication of Standard Operating Procedures and methodology changes, (2) the number of staff working on NICE appraisals, (3) the number of Appraisal Committee meetings required, and (4) external input required from Economic Reference Groups, clinicians, patient organisations, and manufacturers.

NHS England’s Board agreed, on 25 February 2016, a way forward which will see the proposed new arrangements for the Cancer Drugs Fund (CDF) going live on 1 July 2016.

We expect both NHS England and the National Institute for Health and Care Excellence (NICE) to work together to ensure that both organisations have the necessary capability and capacity to implement these proposals.

The NICE Board will be considering the implications of NHS England’s decision at its meeting on 16 March 2015.

The Accelerated Access Review is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for NHS patients to innovative and cost effective new medicines and the CDF.